Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$464.92 USD
-12.98 (-2.72%)
Updated Sep 20, 2024 04:00 PM ET
Pre-Market: $465.10 +0.18 (0.04%) 8:04 AM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRTX 464.92 -12.98(-2.72%)
Will VRTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
Other News for VRTX
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary
Vertex treatment of myotonic dystrophy type 1 granted FDA orphan designation
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript)
Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug